Arthralgia Market

 Market Overview:

The 7 major arthralgia markets reached a value of US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.12% during 2024-2034.

The arthralgia market has been comprehensively analyzed in IMARC's new report titled "Arthralgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arthralgia refers to a medical condition in which there's pain or discomfort in one or more joints of the body. This disease can affect any joint in the body, including the knees, shoulders, hips, wrists, fingers, etc. The pain experienced with arthralgia can range from mild to severe and may be accompanied by stiffness, swelling, redness, or a limitation of joint movement. Several other common indications of this disorder include a general feeling of low energy, muscle aches and discomfort, difficulty bending fully, joint clicking, popping or cracking sounds during movement, balance and coordination problems, etc. The diagnosis of the ailment requires a combination of the patient's comprehensive medical history, underlying symptoms, and physical examination. The healthcare provider may also perform several blood tests, like the erythrocyte sedimentation rate and the C-reactive protein test, to identify markers that indicate inflammation in the body. A joint fluid analysis is further recommended to rule out other possible causes in patients. Numerous imaging studies, such as X-rays, ultrasounds, magnetic resonance imaging, etc., are utilized to provide detailed pictures of the joints and surrounding structures. 

The increasing prevalence of autoimmune diseases, in which the body's defense system mistakenly attacks the joints, leading to inflammation and pain, is primarily driving the arthralgia market. In addition to this, the rising incidences of several associated risk factors, including injuries, trauma, hormonal disorders, joint dislocation, vitamin deficiencies, bacterial, viral and fungal infections, etc., are also bolstering the market growth. Furthermore, the escalating adoption of nonsteroidal anti-inflammatory drugs, such as ibuprofen and naproxen, that help to alleviate pain and provide symptom relief in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical and occupational therapies, which aim to improve joint flexibility, strength, functional tasks, and range of motion, is also creating a positive outlook for the market. Moreover, the widespread demand for transcutaneous electrical nerve stimulation techniques for the treatment of this illness, since they utilize low-voltage electrical currents to disrupt pain signals, thereby boosting a patient's mental health and quality of life, is expected to drive the arthralgia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the arthralgia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for arthralgia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arthralgia market in any manner.

Key Highlights:

• The prevalence of arthralgia is higher in boys than in girls, and it increases with age.
• The age-adjusted prevalence of diagnosed arthritis among adults in the United States was noted to be 18.9%.
• Among adults over 60, the incidence of hip pain is 12 to 15%.
• Arthralgia may be self-limiting, improving after three months of therapy, but for many women, it is chronic.
• Arthralgia is a typical adverse effect of aromatase inhibitor (AI) therapy, affecting up to 36% of patients.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the arthralgia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the arthralgia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current arthralgia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the arthralgia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the arthralgia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the arthralgia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of arthralgia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of arthralgia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of arthralgia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with arthralgia across the seven major markets?
• What is the size of the arthralgia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of arthralgia?
• What will be the growth rate of patients across the seven major markets?
   

Arthralgia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for arthralgia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arthralgia market?
• What are the key regulatory events related to the arthralgia market?
• What is the structure of clinical trial landscape by status related to the arthralgia market?
• What is the structure of clinical trial landscape by phase related to the arthralgia market?
• What is the structure of clinical trial landscape by route of administration related to the arthralgia market?